May 2007
Volume 48, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2007
Utility of Bevacizumab (avastin®) for the Management of Ocular Inflammatory Illnes Complications
Author Affiliations & Notes
  • J. G. Guzman
    Enfermedades Inflamatorias oculares, Fundacion Hospital Nuestra Senora de la Luz, Mexico, Mexico
  • E. Lopez
    Enfermedades Inflamatorias oculares, Fundacion Hospital Nuestra Senora de la Luz, Mexico, Mexico
  • F. Martinez
    Enfermedades Inflamatorias oculares, Fundacion Hospital Nuestra Senora de la Luz, Mexico, Mexico
  • T. Valdez
    Enfermedades Inflamatorias oculares, Fundacion Hospital Nuestra Senora de la Luz, Mexico, Mexico
  • Footnotes
    Commercial Relationships J.G. Guzman, None; E. Lopez, None; F. Martinez, None; T. Valdez, None.
  • Footnotes
    Support None.
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 275. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      J. G. Guzman, E. Lopez, F. Martinez, T. Valdez; Utility of Bevacizumab (avastin®) for the Management of Ocular Inflammatory Illnes Complications. Invest. Ophthalmol. Vis. Sci. 2007;48(13):275.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose:: To evaluate utility and safety of the use of Intravitreal Bevacizumab for the treatment of ocular inflamatory illness complications.

Methods:: we applied 1.87mg of intravitreal Bevacizumab for the treatment of ocular inflammatory illness complications, and evaluated patient's clinical course, BCVA and complications at 1,7,30 and 90 days after the intravitreal injection.

Results:: We included 8 eyes of 7 patients, 1 male and 6 female, with an average age of 20 years, 2 eyes with Cystoid Macular Edema (1 secondary to Pars Planitis and 1 secondary to HLAB27 (+) anterior uveitis), 2 eyes with rubeosis iridis (both secondary to Vogt-Koyanagi-Harada disease), 2 eyes with coroidal neovascularisation (1 secondary to Toxoplasmosis and 1 secondary to Inner Punctate Choroiditis), 1 eye with Branch Retinal Arterial Occlusion (secondary to Wegener's Granulomatosis) and 1 eye with neovascularisation of the peripherial retina (secondary to Pars Planitis).We observed improvement on clinical course and BCVA in all patients treated, and we did not find any complication associated with the use of intravitreal bevacizumab.

Conclusions:: We concluded that the use of intravitreal bevacizumab is useful and safe in the management of ocular inflammatory illness complications. We need a longer study and to include more patients to prove its utility and safety

Clinical Trial:: Hospital Nuestra Señora de la Luz I.A.P. Mexico

Keywords: inflammation • choroid: neovascularization • uvea 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×